However, experts at USC were able to draw upon a big cohort of healthy kids to identify FeNO as a potential biomarker for asthma advancement, Bastain said. Further studies are needed to create whether FeNO can be used in the clinical placing to assess a child’s individual risk for developing asthma. Asthma is an extremely important clinical and public medical condition, and there is still much to be learned about the causes of asthma prior to the burden of asthma could be reduced, said Frank Gilliland, M.D., Ph.D., professor of preventive medicine at the Keck College of Medicine, director of the Southern California Environmental Health Sciences Center and senior writer of the scholarly study.Premium pricing of AMG-162 shall propel the product sales of this agent. The new Pharmacor study entitled Osteoporosis also finds that the full total osteoporosis market – – including osteopenia – – increase at a 4.6 percent annual rate. Elements that will drive the market’s development include substantial boosts in the drug-treated individual population and the launch of new brokers that require less-frequent administration and offer novel mechanisms of action. Related StoriesNew protein product lowers cholesterol, prevents osteoporosisElderly women should take more vitamin D supplementation during the wintertime, suggests researchersTARSA Therapeutics' TBRIA NDA recognized by FDA for review’Much of the growth will be because of the launch of new bisphosphonates, including Roche’s Boniva/Bonviva , Novartis’s Zometa , and Amgen’s novel biological agent, the RANKL inhibitor AMG – 162,’ said Donny Wong, Ph.D., analyst at Decision Assets.